148 related articles for article (PubMed ID: 34345964)
1. EGFRisopred: a machine learning-based classification model for identifying isoform-specific inhibitors against EGFR and HER2.
Saini R; Agarwal SM
Mol Divers; 2022 Jun; 26(3):1531-1543. PubMed ID: 34345964
[TBL] [Abstract][Full Text] [Related]
2. TMLRpred: A machine learning classification model to distinguish reversible EGFR double mutant inhibitors.
Saini R; Fatima S; Agarwal SM
Chem Biol Drug Des; 2020 Sep; 96(3):921-930. PubMed ID: 33058464
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
5. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
[TBL] [Abstract][Full Text] [Related]
6. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
7. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
9. Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities - Part 1.
Das D; Xie L; Wang J; Xu X; Zhang Z; Shi J; Le X; Hong J
Bioorg Med Chem Lett; 2019 Feb; 29(4):591-596. PubMed ID: 30600209
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.
Xue L; Maihle NJ; Yu X; Tang SC; Liu HY
Mol Pharm; 2018 Nov; 15(11):4801-4813. PubMed ID: 30222359
[TBL] [Abstract][Full Text] [Related]
11. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
13. The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells.
Yang Y; Choppavarapu L; Fang K; Naeini AS; Nosirov B; Li J; Yang K; He Z; Zhou Y; Schiff R; Li R; Hu Y; Wang J; Jin VX
Biochim Biophys Acta Gene Regul Mech; 2020 Nov; 1863(11):194631. PubMed ID: 32956836
[TBL] [Abstract][Full Text] [Related]
14. Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[g]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers.
Ghorab MM; Alsaid MS; Soliman AM
Bioorg Chem; 2018 Oct; 80():611-620. PubMed ID: 30041137
[TBL] [Abstract][Full Text] [Related]
15. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
17. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
18. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
Li D; Ambrogio L; Shimamura T; Kubo S; Takahashi M; Chirieac LR; Padera RF; Shapiro GI; Baum A; Himmelsbach F; Rettig WJ; Meyerson M; Solca F; Greulich H; Wong KK
Oncogene; 2008 Aug; 27(34):4702-11. PubMed ID: 18408761
[TBL] [Abstract][Full Text] [Related]
19. Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer.
Schroeder RL; Stevens CL; Sridhar J
Molecules; 2014 Sep; 19(9):15196-212. PubMed ID: 25251190
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold.
Yin S; Tang C; Wang B; Zhang Y; Zhou L; Xue L; Zhang C
Eur J Med Chem; 2016 Sep; 120():26-36. PubMed ID: 27187856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
